Physician profile
Mark B Didea
NPI 1790733772
$1,866.40
in general payments reported to CMS, 2019-2025
22 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $154 · 2021: $120 · 2022: $292 · 2023: $280 · 2024: $389 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $218.41 | 2024-2025 | |
| Corium, LLC | $208.55 | 2021-2022 | |
| Kaleo, INC. | $195.71 | 2019-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $189.53 | 2019-2025 | Bexsero, Pediarix, Menveo |
| Merck Sharp & Dohme LLC | $150.26 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $130.07 | 2019-2023 | Doc Band |
| Ironshore Pharmaceuticals INC. | $125.48 | 2020 | |
| Dynavax Technologies Corporation | $124.98 | 2019 | |
| Pfizer INC. | $115.95 | 2019-2025 | |
| Nevro Corp. | $95.66 | 2022 | |
| Sanofi Pasteur INC. | $49.22 | 2023 | |
| Phadia US INC. | $35.79 | 2023-2025 | Immunocap |
| Alk-Abello, INC | $34.63 | 2025 | Neffy |
| Abbott Laboratories | $30.08 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $27.24 | 2025 | Neffy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $23.92 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $23.26 | 2024 | Ycanth |
| Aimmune Therapeutics, INC. | $22.82 | 2023 | |
| Nestle Healthcare Nutrition INC. | $20.56 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.43 | 2024 | Flumist Quadrivalent |
| Mylan Pharmaceuticals INC. | $14.52 | 2019 | |
| Tris Pharma INC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Didea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.